January 27, 2017

January 27, 2017

An Overview of the Updated HPV Vaccine Recommendations
Targeted Oncology, Jan. 26
The CDC and NCI offered a grant to NCI-designated cancer centers to do an environmental scan in their area of facilitators and barriers related to vaccination, and that really got a lot of people motivated. In fact, 18 institutions were given the grant, but there were so many more centers that wanted to be involved. Then this ongoing conversation started, and they ended up having the first summit at Moffitt Cancer Center, where we got together to talk about how we would all be doing this.

New cancer-fighting assets for Moffitt Cancer Center network
Florida Trend Magazine – Jan. 26
In November, Moffitt Cancer Center leaders unveiled plans for a 10-year, $800-million expansion that includes a new hospital wing, clinical support building and additional outpatient and research facilities. Leaders hope to raise $500 million and finance the rest with a bond backed by cigarette tax revenue.

Reusse: Former WCCO anchor Fritz still tells a good story
Star Tribune – Jan. 26
Rubin sent Fritz to the Moffitt Cancer Center in Tampa, among the highest-rated in the United States, rather than starting an aggressive course of chemo. As it turned out, that’s what has Ralph Jon approaching two years of survival.

Kim Herslow will ride Soraya II for the Moffitt Cancer Center’s focus on ovarian cancer
HorseJunkiesUnited.com – Jan. 26
“Moffitt Cancer Center was selected since my father was treated there for melanoma and liver cancer,” Marilyn explained. “I wanted the funds to go to ovarian cancer since I was diagnosed with Stage IV ovarian cancer at age 20 and given a 5% survival chance. After surgery, radiation and chemotherapy I was cured and will be celebrating my 70th birthday next week.”

Evidence With Iron Chelation Therapy in MDS
OncLive – Jan. 25
Rami S. Komrokji, MD: To set the stage, I’m going to also talk about the iron chelation role, in general, in MDS patients, because obviously, there is a school of thought. Some are believers in the role of iron chelation, some are not. You built a nice story, that patients who are blood-transfusion–dependent, they don’t do as well.

Experience with Omacetaxine for TKI-Resistant TKI CML
OncLive – Jan. 25
Javier Pinilla-Ibarz, MD, PhD: Omacetaxine has been tested, and been approved for the treatment of chronic myeloid leukemia after intolerance or resistance to more than 2 tyrosine kinase inhibitors. In this setting, there are several trials that were published, and have been done a few years ago, where this drug showed efficacy in the control of the disease, either in the resistance or intolerance setting of chronic myeloid leukemia.

Mill Creek community pours out support for teacher battling cancer
Winnett Daily Post – Jan. 25
A part-time math teacher at Mill Creek, Ashley also coaches competitive cheerleading at the school. Her doctor visits and other treatments are at the Moffitt Cancer Center in Tampa, Fla., where she sees a specialist in neuroendocrine cancer Emory Medical Center and Gwinnett Medical Center.

Two Days After Surgery for Cervical Cancer, Erin Andrews was Back at Work
Yahoo – Jan. 24
Hye Sook Chon, M.D., a gynecological oncologist at the Moffitt Cancer Center, tells Yahoo Beauty that recovery time varies for cervical cancer surgery, depending on what stage a woman’s cancer is in, and what type of surgery she had.

Dr. Strosberg on Future of 177Lu-Dotatate Therapy in Neuroendocrine Tumors
OncLive – Jan. 24
Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the future of using 177Lu-dotatate (Lutathera) therapy to treat patients with neuroendocrine tumors.

Alternative Mechanism for Treatment of Resistant CML
OncLive - Jan. 24
Javier Pinilla-Ibarz, MD, PhD: When we treat patients with TKIs, tyrosine kinase inhibitors, sometimes these drugs don’t work. These are a relatively small percentage of patients, but sometimes after 1, 2, 3, or even 4 TKIs, we encounter the clinical situation where TKIs are not working anymore. These are the times that we really try to look for non-TKI alternatives, in this case, some other drugs that can have a completely different mechanism of action of the classical tyrosine kinase inhibition.

George Edgecomb Society hosts fundraiser with Vivica Fox
Florida Sentinel – Jan. 23
Moffitt Cancer Center hosted a fundraiser last week. The event was held to raise funds for cancer research and health disparity.

Florida Hospital Association appoints Jack Kolosky chairman: 3 takeaways
Becker’s Hospital Review – Jan. 23
The Florida Hospital Association, comprised of 205 hospitals and health systems, selected Jack Kolosky to serve as its new chairman, according to the Tampa Bay Business Journal. Here are three takeaways:

  1. Mr. Kolosky is president of Tampa, Fla.-based Moffitt Cancer Center's hospital corp.
  2. He is also corporate executive vice president and COO of Moffitt.
  3. He replaces Jim Burkhart as chairman, after Mr. Burkhart resigned as president and CEO of Tampa General Hospital.


Monitoring for Iron Overload in Transfusion-Dependent MDS
OncLive – Jan. 23
Rami S. Komrokji, MD: For me, I think with the iron overload, nobody would disagree that it’s a problem in patients with MDS. And, as Jamile mentioned, usually patients, when they get to 15 to 20 units of blood, each having about 200 mg of iron, they are at the threshold where they could get iron overload.

Mosi to honor two new scientists in Florida Hall of Fame at Gasparilla Children's Parade
WTSP – Jan. 21
Dr. William Dalton of M2Gen, Moffitt Cancer Center, and USF, along with Dr. Yogi Goswami of USF Clean Energy Center will be honored at this year's Gasparilla Children's Parade on Saturday.

Defining Suboptimal Response to BCR-ABL TKI Therapy in CML
OncLive – Jan. 20
Javier Pinilla-Ibarz, MD, PhD: In order to identify suboptimal response to TKI (tyrosine kinase inhibitor) therapies these days, we really follow the NCCN guidelines. There are very specific recommendations about the milestones that patients need to achieve, at certain times, to be able to have very good outcomes at the end. At 3 months, 6 months, and 12 months, patients need to be at specific PCR levels or cytogenetic levels. And, at this point, although there are not many, there is a proportion of patients who still cannot achieve these milestones, for whom we do recommend to switch therapies.

Red pigment in red peppers and oranges linked to a lower risk of lung cancer
Medical Xpress – Jan. 20
It's the first time nicotine receptors on the surface of lung cells have been linked to BCX, according to Srikumar Chellappan, a cancer biologist at the H. Lee Moffitt Cancer Center & Research Institute in Tampa, Florida. More research is needed to fully understand how BCX slows lung cell production of nicotine receptors, Chellappan said. "A significant amount of molecular studies would be needed to understand how this agent functions in chemoprevention," he noted.


Please note we cannot guarantee the accuracy or availability of links. The stories belong to the respective publishers, and links may expire. Some news sites require you to register and select a password in order to retrieve articles, but most usually do not charge a fee to retrieve these news stories.